Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tenaya Therapeutics Inc TNYA

Healthcare Biotechnology
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s... see more

Recent & Breaking News (NDAQ:TNYA)

Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference

Business Wire May 20, 2022

Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Business Wire May 11, 2022

Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting

Business Wire May 3, 2022

Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022

Business Wire April 28, 2022

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

Business Wire March 24, 2022

Tenaya Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Updates

Business Wire March 23, 2022

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

Business Wire January 31, 2022

Tenaya Therapeutics Provides 2022 Business Updates

Business Wire January 10, 2022

Tenaya Therapeutics Appoints Karah Parschauer, J.D., to Its Board of Directors and Joanna Auch as Senior Vice President of People and Culture

Business Wire December 22, 2021

Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors

Business Wire November 22, 2021

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference

Business Wire November 19, 2021

Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

Business Wire November 10, 2021

Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress

Business Wire October 12, 2021

Tenaya Therapeutics to Participate in Upcoming Investor and Industry Conferences

Business Wire September 30, 2021

Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

Business Wire September 8, 2021

Tenaya Therapeutics to Present at Morgan Stanley 19th Annual Global Healthcare Conference

Business Wire August 31, 2021

Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Business Wire August 3, 2021

Tenaya Therapeutics Announces Pricing of Upsized Initial Public Offering

Business Wire July 29, 2021